{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:21:26Z","timestamp":1793834486649,"version":"4.6.1"},"reference-count":73,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T00:00:00Z","timestamp":1687219200000},"content-version":"am","delay-in-days":354,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["DK099052"],"award-info":[{"award-number":["DK099052"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["DK118959"],"award-info":[{"award-number":["DK118959"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gastrojournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterology"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1053\/j.gastro.2022.04.016","type":"journal-article","created":{"date-parts":[[2022,6,20]],"date-time":"2022-06-20T05:14:23Z","timestamp":1655702063000},"page":"118-136","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":163,"title":["AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Constipation"],"prefix":"10.1053","volume":"163","author":[{"given":"Lin","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahnaz","family":"Sultan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Lembo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Nicholas","family":"Verne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Smalley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel J.","family":"Heidelbaugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.gastro.2022.04.016_bib1","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.cgh.2012.02.029","article-title":"Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis","volume":"10","author":"Lovell","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2022.04.016_bib2","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1053\/j.gastro.2019.12.021","article-title":"Prevalence of Rome IV functional bowel disorders among adults in the United States, Canada, and the United Kingdom","volume":"158","author":"Palsson","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2022.04.016_bib3","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1053\/j.gastro.2020.04.014","article-title":"Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome Foundation Global Study","volume":"160","author":"Sperber","year":"2021","journal-title":"Gastroenterology"},{"issue":"Suppl","key":"10.1053\/j.gastro.2022.04.016_bib4","doi-asserted-by":"crossref","first-page":"S98","DOI":"10.1097\/MCG.0b013e31821fbf44","article-title":"Quality of life in patients with irritable bowel syndrome","volume":"45","author":"Monnikes","year":"2011","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"10.1053\/j.gastro.2022.04.016_bib5","doi-asserted-by":"crossref","first-page":"643","DOI":"10.2165\/00019053-200119060-00003","article-title":"Quality of life in irritable bowel syndrome","volume":"19","author":"Lea","year":"2001","journal-title":"Pharmacoeconomics"},{"key":"10.1053\/j.gastro.2022.04.016_bib6","doi-asserted-by":"crossref","first-page":"324","DOI":"10.5056\/jnm.2012.18.3.324","article-title":"Psychiatric, somatic and other functional gastrointestinal disorders in patients with irritable bowel syndrome at a tertiary care center","volume":"18","author":"Singh","year":"2012","journal-title":"J\u00a0Neurogastroenterol Motil"},{"key":"10.1053\/j.gastro.2022.04.016_bib7","first-page":"755","article-title":"A\u00a0systematic review of the economic and humanistic burden of illness in irritable bowel syndrome and chronic constipation","volume":"19","author":"Nellesen","year":"2013","journal-title":"J\u00a0Manag Care Pharm"},{"key":"10.1053\/j.gastro.2022.04.016_bib8","doi-asserted-by":"crossref","first-page":"8103","DOI":"10.3748\/wjg.v21.i26.8103","article-title":"Patients with irritable bowel syndrome-diarrhea have lower disease-specific quality of life than irritable bowel syndrome-constipation","volume":"21","author":"Singh","year":"2015","journal-title":"World J Gastroenterol"},{"key":"10.1053\/j.gastro.2022.04.016_bib9","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1007\/BF01303162","article-title":"U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact","volume":"38","author":"Drossman","year":"1993","journal-title":"Dig Dis Sci"},{"key":"10.1053\/j.gastro.2022.04.016_bib10","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1038\/s41395-018-0262-x","article-title":"Work productivity and activity impairment in irritable bowel syndrome (IBS): a multifaceted problem","volume":"113","author":"Frandemark","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2022.04.016_bib11","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1016\/j.clinthera.2006.10.010","article-title":"Health-related quality of life, work productivity, and health care resource utilization of subjects with irritable bowel syndrome: baseline results from LOGIC (Longitudinal Outcomes Study of Gastrointestinal Symptoms in Canada), a naturalistic study","volume":"28","author":"Pare","year":"2006","journal-title":"Clin Ther"},{"key":"10.1053\/j.gastro.2022.04.016_bib12","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1046\/j.1365-2036.2003.01456.x","article-title":"The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects","volume":"17","author":"Hungin","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2022.04.016_bib13","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1111\/j.1365-2036.2005.02463.x","article-title":"Irritable bowel syndrome in the United States: prevalence, symptom patterns and impact","volume":"21","author":"Hungin","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2022.04.016_bib14","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1016\/j.cgh.2019.08.016","article-title":"Effects of irritable bowel syndrome on daily activities vary among subtypes based on results from the IBS in America survey","volume":"17","author":"Ballou","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2022.04.016_bib15","series-title":"Rome IV Diagnostic Algorithms for Common GI Symptoms","year":"2016"},{"key":"10.1053\/j.gastro.2022.04.016_bib16","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1053\/j.gastro.2014.09.002","article-title":"American Gastroenterological Association Institute Technical Review on the pharmacological management of irritable bowel syndrome","volume":"147","author":"Chang","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2022.04.016_bib17","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1053\/j.gastro.2014.09.001","article-title":"American Gastroenterological Association Institute guideline on the pharmacological management of irritable bowel syndrome","volume":"147","author":"Weinberg","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2022.04.016_bib18","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.cgh.2013.02.001","article-title":"The AGA Institute process for developing clinical practice guidelines part one: grading the evidence","volume":"11","author":"Sultan","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2022.04.016_bib19","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1111\/j.1572-0241.2007.01283.x","article-title":"Characterization of health related quality of life (HRQOL) for patients with functional bowel disorder (FBD) and its response to treatment","volume":"102","author":"Drossman","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2022.04.016_bib20","series-title":"Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0","year":"2011"},{"key":"10.1053\/j.gastro.2022.04.016_bib21","series-title":"GRADEpro Guideline Development Tool. Evidence Prime","author":"Brozek","year":"2019"},{"key":"10.1053\/j.gastro.2022.04.016_bib22","doi-asserted-by":"crossref","first-page":"227ra36","DOI":"10.1126\/scitranslmed.3007790","article-title":"Intestinal inhibition of the Na+\/H+ exchanger 3 prevents cardiorenal damage in rats and inhibits Na+ uptake in humans","volume":"6","author":"Spencer","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1053\/j.gastro.2022.04.016_bib23","doi-asserted-by":"crossref","first-page":"S-57","DOI":"10.1016\/S0016-5085(11)60233-3","article-title":"Visceral antinociceptive effects of RDX5791, a first-in-class minimally systemic NHE3 inhibitor on stress-induced colorectal hypersensitivity to distension in rats","volume":"140","author":"Eutamene","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2022.04.016_bib24","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/ajg.2017.41","article-title":"Tenapanor treatment of patients with constipation-predominant irritable bowel syndrome: a phase 2, randomized, placebo-controlled efficacy and safety trial","volume":"112","author":"Chey","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2022.04.016_bib25","doi-asserted-by":"crossref","first-page":"281","DOI":"10.14309\/ajg.0000000000000516","article-title":"Efficacy of tenapanor in treating patients with irritable bowel syndrome with constipation: a 12-week, placebo-controlled phase 3 trial (T3MPO-1)","volume":"115","author":"Chey","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2022.04.016_bib26","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.14309\/ajg.0000000000001056","article-title":"Efficacy of tenapanor in treating patients with irritable bowel syndrome with constipation: a 26-week, placebo-controlled phase 3 trial (T3MPO-2)","volume":"116","author":"Chey","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2022.04.016_bib27","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1053\/j.gastro.2016.02.031","article-title":"Bowel disorders","volume":"150","author":"Mearin","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2022.04.016_bib28","doi-asserted-by":"crossref","first-page":"920","DOI":"10.3109\/00365529709011203","article-title":"Stool form scale as a useful guide to intestinal transit time","volume":"32","author":"Lewis","year":"1997","journal-title":"Scand J Gastroenterol"},{"key":"10.1053\/j.gastro.2022.04.016_bib30","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.295","article-title":"Therapeutically targeting guanylate cyclase-C: computational modeling of plecanatide, a uroguanylin analog","volume":"5","author":"Brancale","year":"2017","journal-title":"Pharmacol Res Perspect"},{"key":"10.1053\/j.gastro.2022.04.016_bib31","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.3748\/wjg.v24.i17.1888","article-title":"Oral treatment with plecanatide or dolcanatide attenuates visceral hypersensitivity via activation of guanylate cyclase-C in rat models","volume":"24","author":"Boulete","year":"2018","journal-title":"World J Gastroenterol"},{"key":"10.1053\/j.gastro.2022.04.016_bib32","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/s41395-018-0026-7","article-title":"Efficacy, safety, and tolerability of plecanatide in patients with irritable bowel syndrome with constipation: results of two phase 3 randomized clinical trials","volume":"113","author":"Brenner","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2022.04.016_bib33","doi-asserted-by":"crossref","first-page":"S541","DOI":"10.14309\/00000434-201410002-01831","article-title":"Plecanatide, a novel uroguanylin analog: a 12-week, randomized, double-blind, placebo-controlled, dose-ranging trial to evaluate efficacy and safety in patients with irritable bowel syndrome with constipation (IBS-C)","author":"Miner","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2022.04.016_bib34","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/ajg.2017.495","article-title":"Efficacy and tolerability of guanylate cyclase-C agonists for irritable bowel syndrome with constipation and chronic idiopathic constipation: a systematic review and meta-analysis","volume":"113","author":"Shah","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2022.04.016_bib35","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1016\/j.pain.2013.05.044","article-title":"Gastrointestinal pain: unraveling a novel endogenous pathway through uroguanylin\/guanylate cyclase-C\/cGMP activation","volume":"154","author":"Silos-Santiago","year":"2013","journal-title":"Pain"},{"key":"10.1053\/j.gastro.2022.04.016_bib36","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3389\/fnmol.2014.00031","article-title":"Guanylate cyclase-C\/cGMP: an emerging pathway in the regulation of visceral pain","volume":"7","author":"Hannig","year":"2014","journal-title":"Front Mol Neurosci"},{"key":"10.1053\/j.gastro.2022.04.016_bib37","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1053\/j.gastro.2013.08.017","article-title":"Linaclotide inhibits colonic nociceptors and relieves abdominal pain via guanylate cyclase-C and extracellular cyclic guanosine 3',5'-monophosphate","volume":"145","author":"Castro","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2022.04.016_bib38","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1038\/ajg.2012.255","article-title":"A\u00a012-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation","volume":"107","author":"Rao","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2022.04.016_bib39","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1053\/j.gastro.2010.08.041","article-title":"Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation","volume":"139","author":"Johnston","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2022.04.016_bib40","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1038\/ajg.2012.254","article-title":"Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety","volume":"107","author":"Chey","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2022.04.016_bib41","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1111\/jgh.14086","article-title":"Linaclotide in irritable bowel syndrome with constipation: A Phase 3 randomized trial in China and other regions","volume":"33","author":"Yang","year":"2018","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2022.04.016_bib42","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1053\/j.gastro.2005.11.061","article-title":"Functional bowel disorders","volume":"130","author":"Longstreth","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2022.04.016_bib43","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/j.1365-2036.2011.04983.x","article-title":"Safety and patient outcomes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with constipation","volume":"35","author":"Chey","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2022.04.016_bib44","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1053\/j.gastro.2018.08.021","article-title":"Efficacy of secretagogues in patients with irritable bowel syndrome with constipation: systematic review and network meta-analysis","volume":"155","author":"Black","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2022.04.016_bib45","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/j.1365-2036.2012.05011.x","article-title":"Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders","volume":"35","author":"Tack","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2022.04.016_bib46","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1177\/1074248409340158","article-title":"Lack of association of tegaserod with adverse cardiovascular outcomes in a matched case-control study","volume":"14","author":"Anderson","year":"2009","journal-title":"J\u00a0Cardiovasc Pharmacol Ther"},{"key":"10.1053\/j.gastro.2022.04.016_bib47","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1177\/1074248409360357","article-title":"Tegaserod and the risk of cardiovascular ischemic events: an observational cohort study","volume":"15","author":"Loughlin","year":"2010","journal-title":"J\u00a0Cardiovasc Pharmacol Ther"},{"key":"10.1053\/j.gastro.2022.04.016_bib48","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.14309\/ajg.0000000000001313","article-title":"Tegaserod for irritable bowel syndrome with constipation in women younger than 65 years without cardiovascular disease: pooled analyses of 4 controlled trials","volume":"116","author":"Shah","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2022.04.016_bib49","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1046\/j.1365-2036.2001.01094.x","article-title":"Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation","volume":"15","author":"Muller-Lissner","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2022.04.016_bib50","first-page":"266","article-title":"The 5-HT4 partial agonist, tegaserod, improves abdominal discomfort\/pain and normalizes altered bowel function in irritable bowel syndrome (IBS)","volume":"94","author":"Lefkowitz","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2022.04.016_bib51","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1046\/j.1365-2036.2002.01372.x","article-title":"A\u00a0randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation","volume":"16","author":"Novick","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2022.04.016_bib53","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2147\/tcrm.2007.3.1.107","article-title":"Tegaserod in the treatment of irritable bowel syndrome (IBS) with constipation as the prime symptom","volume":"3","author":"Layer","year":"2007","journal-title":"Ther Clin Risk Manag"},{"key":"10.1053\/j.gastro.2022.04.016_bib54","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1136\/gut.52.5.671","article-title":"An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome","volume":"52","author":"Kellow","year":"2003","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2022.04.016_bib55","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1080\/00365520310006748","article-title":"A\u00a0double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome","volume":"39","author":"Nyhlin","year":"2004","journal-title":"Scand J Gastroenterol"},{"key":"10.1053\/j.gastro.2022.04.016_bib56","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1136\/gut.2005.077503","article-title":"A\u00a0controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome","volume":"55","author":"Tack","year":"2006","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2022.04.016_bib57","doi-asserted-by":"crossref","first-page":"G942","DOI":"10.1152\/ajpgi.00264.2005","article-title":"Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers","volume":"290","author":"Camilleri","year":"2006","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1053\/j.gastro.2022.04.016_bib58","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1365-2036.2008.03881.x","article-title":"Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome\u2014results of two randomized, placebo-controlled studies","volume":"29","author":"Drossman","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2022.04.016_bib59","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1038\/ajg.2013.197","article-title":"Randomized clinical trial: macrogol\/PEG 3350 plus electrolytes for treatment of patients with constipation associated with irritable bowel syndrome","volume":"108","author":"Chapman","year":"2013","journal-title":"Am J Gastroenterol"},{"issue":"Suppl 1","key":"10.1053\/j.gastro.2022.04.016_bib60","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1038\/ajg.2014.187","article-title":"American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation","volume":"109","author":"Ford","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2022.04.016_bib61","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1053\/j.gastro.2016.03.035","article-title":"Rome IV-functional GI disorders: disorders of gut-brain interaction","volume":"150","author":"Drossman","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2022.04.016_bib62","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1053\/j.gastro.2017.11.279","article-title":"Neuromodulators for functional gastrointestinal disorders (disorders of gut-brain interaction): a rome foundation working team report","volume":"154","author":"Drossman","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2022.04.016_bib63","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1111\/j.1365-2036.2008.03633.x","article-title":"Clinical trial: the effect of amitriptyline in patients with diarrhoea-predominant irritable bowel syndrome","volume":"27","author":"Vahedi","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2022.04.016_bib64","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S1542-3565(03)70039-1","article-title":"The selective serotonin reuptake inhibitor fluoxetine does not change rectal sensitivity and symptoms in patients with irritable bowel syndrome: a double blind, randomized, placebo-controlled study","volume":"1","author":"Kuiken","year":"2003","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2022.04.016_bib65","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.cgh.2009.09.008","article-title":"Citalopram provides little or no benefit in nondepressed patients with irritable bowel syndrome","volume":"8","author":"Ladabaum","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2022.04.016_bib66","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1176\/appi.psy.50.1.78","article-title":"A\u00a0double-blind, randomized, placebo-controlled trial of paroxetine controlled-release in irritable bowel syndrome","volume":"50","author":"Masand","year":"2009","journal-title":"Psychosomatics"},{"key":"10.1053\/j.gastro.2022.04.016_bib67","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1111\/j.1572-0241.2004.04127.x","article-title":"Paroxetine to treat irritable bowel syndrome not responding to high-fiber diet: a double-blind, placebo-controlled trial","volume":"99","author":"Tabas","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2022.04.016_bib68","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/s10620-007-9830-4","article-title":"Antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial","volume":"53","author":"Talley","year":"2008","journal-title":"Dig Dis Sci"},{"key":"10.1053\/j.gastro.2022.04.016_bib69","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.coph.2008.07.012","article-title":"Psychotropic agents in functional gastrointestinal disorders","volume":"8","author":"Grover","year":"2008","journal-title":"Curr Opin Pharmacol"},{"key":"10.1053\/j.gastro.2022.04.016_bib70","first-page":"17","article-title":"Interactions between symptoms and motor and visceral sensory responses of irritable bowel syndrome patients to spasmolytics (antispasmodics)","volume":"18","author":"Khalif","year":"2009","journal-title":"J\u00a0Gastrointestin Liver Dis"},{"key":"10.1053\/j.gastro.2022.04.016_bib71","first-page":"CD003460","article-title":"Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome","author":"Ruepert","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1053\/j.gastro.2022.04.016_bib72","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1053\/j.gastro.2020.05.059","article-title":"AGA Clinical Practice Guidelines on the role of probiotics in the management of gastrointestinal disorders","volume":"159","author":"Su","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2022.04.016_bib73","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1053\/j.gastro.2016.02.014","article-title":"Rome IV diagnostic questionnaires and tables for investigators and clinicians","volume":"150","author":"Palsson","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2022.04.016_bib74","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.cgh.2021.06.032","article-title":"The transition from Rome III to Rome IV irritable bowel syndrome: what we gain and lose","volume":"20","author":"Shin","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2022.04.016_bib76","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.jval.2016.11.001","article-title":"Development of the diary for irritable bowel syndrome symptoms to assess treatment benefit in clinical trials: foundational qualitative research","volume":"20","author":"Fehnel","year":"2017","journal-title":"Value Health"}],"container-title":["Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508522003900?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508522003900?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T09:51:02Z","timestamp":1762163462000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0016508522003900"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":73,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S0016508522003900"],"URL":"https:\/\/doi.org\/10.1053\/j.gastro.2022.04.016","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.742211093.793594354","asserted-by":"object"}]},"ISSN":["0016-5085"],"issn-type":[{"value":"0016-5085","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Constipation","name":"articletitle","label":"Article Title"},{"value":"Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.gastro.2022.04.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by the AGA Institute","name":"copyright","label":"Copyright"}]}}